Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and IrinotecanChiara Cremolini, Daniele Santini, Nicoletta Pella et al.|JAMA Oncology|2018Cited by 418
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al.|The Lancet Oncology|2020Cited by 322
Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer PainElena Bandieri, Marilena Romero, Carla Ripamonti et al.|Journal of Clinical Oncology|2015Cited by 181
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysisFrancesco Passiglia, Antonio Russo, Giuseppe Bronte et al.|Oncotarget|2016Cited by 166
Natural History of Non-Small-Cell Lung Cancer with Bone MetastasesDaniele Santini, Giuseppe Tonini|Scientific Reports|2015Cited by 138